Fundz
Funding, M&A and exec moves matched to your market, from $49/mo billed annually, or $79/mo quarterly. See plans and pricing.See plans →

NanoMosaic is part of a consortium awarded up to $39.2 million by ARPA-H to advance on-demand distributed manufacturing of genetic medicines. This funding will aid the development of a compact, automated system for RNA medicines.

PRIVATESep 08, 2026•about 3 hours ago

Amount Raised

$39.2 Million

Round Type

Venture - Series Unknown

BostonBiotechnology

Description

NanoMosaic announced its participation in a multidisciplinary team awarded up to $39.2 million by ARPA-H. The funds will support the FUSE project, aimed at integrating production and analysis of RNA medicines. NanoMosaic is leading the development of FUSE's analytical and software engine. This innovation aims to change how genetic medicines are manufactured and released.

Company Information

Company

NanoMosaic

Location

Boston, Massachusetts, United States

About

NanoMosaic, a Boston-based biotechnology company, is the only commercial entity to leverage the power of nanoneedles, MosaicNeedlesTM, for protein detection and quantification to develop best-in-class assays for biomarker discovery and validation. The NanoMosaic platform, TessieTM, alleviates the bottlenecks in proteomics analysis and provides an end-to-end solution that enables first of its kind protein interrogation and multi-omics analysis within a single chip on one run. The proprietary technology enables rapid, end user customization for assay development for proteomic and/or nucleic acid content. The NanoMosaic platform allows researchers to push the frontiers in biomarker discovery and diagnostics. www.nanomosaicllc.com CONTACT: Audrey Warner, audrey.warner@tigergenellc.com SOURCE NanoMosaic

Don't miss NanoMosaic's next move

Get an email the moment NanoMosaic raises, hires an exec, or expands, usually minutes after it happens.

One email per event. Unsubscribe anytime.

Predictive Intelligence
Strategic

ML-powered predictions for NanoMosaic's next move

See what Strategic adds

Funding Insights

Based on industry data
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech

NanoMosaic raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick. $29 a month, billed annually, and if it does not pay for itself in a year we refund it.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 200,000+ companies. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.